Cabot Corp

Cabot Corp(CBT)股票分析

$73.780

+0.162 (+0.22%)收盘时

Loading chart…
最高
73.860
开盘
73.780
成交量加权均价
73.42
成交量
411.06K
市值
5.16B
最低
72.620
成交额
30.18M
企业价值/息税折旧摊销前利润(TTM)
6.68

Cabot Corporation is a global specialty chemicals and performance materials company. The Company's principal products are reinforcing and specialty carbons, specialty compounds, conductive additives, carbon nanotubes, fumed metal oxides, inkjet colorants and aerogel. It operates through two segments: Reinforcement Materials and Performance Chemicals. Its reinforcing carbon products are used in tires and industrial products. In addition to its reinforcing carbons, it manufactures engineered elastomer composites (E2C) solutions that are composites of reinforcing carbons and rubber made using its patented elastomer composites manufacturing process. Under the Performance Chemicals segment, it designs, manufactures and sells materials that deliver performance in a range of customer applications across the automotive, construction, infrastructure, inkjet printing, electronics, and consumer products sectors and in applications related to the generation, transmission and storage of energy.

AI 分析 of Cabot Corp (CBT)

持有

Cabot Corp is currently not a strong buy due to its recent earnings decline and technical indicators. The current price is $74.29, and the RSI is at 31.63, indicating oversold conditions. However, the forward P/E ratio is attractive at 9.94, suggesting potential value. The main risk is the significant drop in Q3 earnings, with net income falling to $6 million from $101 million year-over-year, which raises concerns about profitability.

分析师评级(7)

-10.10% 下跌空间
持有
3 买入
4 持有
0 卖出
当前: 73.78
最低
54.00
平均
66.33
最高
80.00

UBS

2026-10-05

目标价

$86

中性

Truist

2026-08-05

目标价

$100

买入

Mizuho

2026-06-25

目标价

$90

中性

JPMorgan

2026-05-13

目标价

$70

减持

UBS

2026-05-08

目标价

$86

中性

估值指标

Cabot Corp(CBT)当前预期市盈率为 9.94,5 年平均预期市盈率为 11.17。

预期市盈率

合理
5 年均值 P/E
11.17
当前P/E
9.94
高估
12.58
低估
9.75

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
6.96
当前EV/EBITDA
6.68
高估
7.63
低估
6.29

预期市销率

合理
5 年均值 P/S
1.05
当前P/S
1.00
高估
1.22
低估
0.88

Alphio AI 对 CBT 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%CBT

$73.88

情景价格

基

基准

基准 · 50%CBT

$69.19

情景价格

悲

悲观

悲观 · 25%CBT

$55.14

情景价格

持有 CBT 的大户

F

Fiduciary Trust Company

+ 持有CBT

+1.54%

3个月收益率

L

Leeward Investments, LLC

+ 持有CBT

+0.11%

3个月收益率

E

EARNEST Partners, LLC

+ 持有CBT

-4.62%

3个月收益率

事件时间线

2026-09-17 (ET)

09:30:00

Cabot Secures $50M Grant from DOE

2026-09-15 (ET)

09:00:00

Cabot Appoints Steve Delahunt as Interim CFO

2026-08-03 (ET)

17:00:00

Cabot Reports Q3 Revenue of $982M, Beating Expectations

17:00:00

Company Adjusts Fiscal 2026 EPS Guidance to $6.15-$6.45

2026-05-05 (ET)

16:50:00

Cabot Sees FY26 Adjusted EPS $6.00-$6.50

资讯

CBT 常见问题 —— 由 Alphio AI 解答

Cabot Corporation is a global specialty chemicals and performance materials company. The Company's principal products are reinforcing and specialty carbons, specialty compounds, conductive additives, carbon nanotubes, fumed metal oxides, inkjet colorants and aerogel. It operates through two segments: Reinforcement Materials and Performance Chemicals. Its reinforcing carbon products are used in tires and industrial products. In addition to its reinforcing carbons, it manufactures engineered elastomer composites (E2C) solutions that are composites of reinforcing carbons and rubber made using its patented elastomer composites manufacturing process. Under the Performance Chemicals segment, it designs, manufactures and sells materials that deliver performance in a range of customer applications across the automotive, construction, infrastructure, inkjet printing, electronics, and consumer products sectors and in applications related to the generation, transmission and storage of energy. It operates in the Basic Materials sector (MISCELLANEOUS CHEMICAL PRODUCTS industry).

Cabot Corp is currently not a strong buy due to its recent earnings decline and technical indicators. The current price is $74.29, and the RSI is at 31.63, indicating oversold conditions. However, the forward P/E ratio is attractive at 9.94, suggesting potential value. The main risk is the significant drop in Q3 earnings, with net income falling to $6 million from $101 million year-over-year, which raises concerns about profitability.

7 analysts cover CBT: 3 rate it Buy, 4 Hold and 0 Sell. The average price target is 66.33.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易